Join to View Full Profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Dr. Kwak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1987 - 1991- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 2015 - 2027
TX State Medical License 2005 - 2024
MD State Medical License 1991 - 2004
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Patients With Multiple Myeloma Start of enrollment: 1995 Jul 01
Publications & Presentations
PubMed
- Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma.Hui-Ju Hsieh, Ryan Urak, Mary C Clark, Larry W Kwak, Stephen J Forman
Molecular Therapy. Methods & Clinical Development. 2025-03-13 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.Swetha Kambhampati Thiruvengadam, Matthew G Mei, Lu Chen, Sandrine Puverel, Robert Chen
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01 - 5 citationsBrentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymp...Alex F Herrera, Jasmine Zain, Kerry J Savage, Tatyana Feldman, Jonathan E Brammer
The Lancet. Haematology. 2024-09-01
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
- Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion: Study ProtocolSattva S Neelapu, D Lynne Smith, Vincent Y Lee, Larry W Kwak, Sheeba K Thomas, BioMed Central
Abstracts/Posters
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-RLarry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Caught in the Crossfire: The Critical Threats Facing Cancer Centers, Research, and Patient CareMarch 21st, 2025- New Cancer Vaccines on the Horizon: Renewed Hope or Hype?December 6th, 2024
- City of Hope Vaccine Experts Report Positive Results on Phase 1 Trial of Personalized Vaccine for Lymphoplasmacytic LymphomaSeptember 19th, 2024
- Join now to see all
Grant Support
- BAFF-R CAR T cell therapy for ALLBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2022–2027
- City of Hope Lymphoma SPOREBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2004–2025
- P1 - Combination Activated T-Cell And Vaccine Therapy In MyelomaNational Cancer Institute2010–2011
- Career Development ProgramNational Cancer Institute2010–2011
- Immunization Of Stem Cell Transplant Donors To Enhance Graft-Versus-Tumor EffectNational Cancer Institute2007–2008
- Cellular And Humoral Immunity Against Myeloma IdiotypeDivision Of Clinical Sciences - Nci2004
- Immunization Of Stem Cell Transplant Donors With MyelomaDivision Of Clinical Sciences - Nci2002–2004
- Genetic Cancer VaccinesDivision Of Clinical Sciences - Nci2000–2004
- Cancer Vaccines For LymphomasDivision Of Clinical Sciences - Nci2000–2004
- Evaluation Of Cellular /Humoral Immunity Against MyelomaDivision Of Clinical Sciences - Nci2003
- Evaluation Of Cellular And Humoral Immunity Against MyelDivision Of Clinical Sciences - Nci2001–2002
- Immunization Of Stem Cell Transplant Donors With MyelomaDivision Of Clinical Sciences - Nci2000
- Evaluation Of Cellular And Humoral Immunity Against Myeloma IdiotypeDivision Of Clinical Sciences - Nci2000
- Idiotype Antigen Vaccine For Follicular LymphomasDivision Of Clinical Sciences - Nci1999
- Evaluation Of Cellular And Humoral Immunity Against IdiotypeDivision Of Clinical Sciences - Nci1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
